Real Viewpoints – Our Q4 Highlights
Welcome to the year-end edition of Real Viewpoints, a newsletter for senior decision makers. In this edition we’ll be discussing rare and orphan disease coverage issues
INSIGHTS AND UPDATES
“Until the evidence is there,” says Dr. Michael Sherman, Point 32Health
Real Viewpoints sat down with Dr. Michael Sherman, the pioneering chief medical officer at Point32Health, who shared his perspectives on coverage issues, rare/orphan diseases, and the special challenge of value-based agreements
“No, we won’t cover the drug – until the evidence is there,” says Dr. Michael Sherman Read here
FEATURED ARTICLE
Commercializing Rare-Disease Therapies is Getting Tougher
For an industry increasingly dominated by these drugs, commercial programs may need to take on the risk once reserved for development. Roger and Rob share their thoughts. Read here
RE Assist has launched!
The first automated program to help connect eligible patients to the financial assistance they need. Read here
PharmaVOICE names Roger Longman as one of the 100 most inspiring leaders in life sciences. Read here
REAL ENDPOINTS THOUGHT-LEADERSHIP IN ACTION
We wish you a very happy holiday season and a New Year filled with peace and prosperity
